Cardiorenal Effectiveness of Empagliflozin vs. GLP-1 Receptor Agonists in Patients with Advanced Chronic Kidney Disease: Results from the EMPRISE study

被引：0
|
作者：
Koenemann, Lisette [1 ]
Htoo, Phyo Than [2 ,3 ]
Patorno, Elisabetta [2 ,3 ]
Tesfaye, Helen [2 ,3 ]
Wexler, Deborah J. [4 ,5 ]
Glynn, Robert J. [2 ,3 ]
Schmedt, Niklas
Deruaz-Luyet, Anouk [6 ]
Schneeweiss, Sebastian [2 ,3 ]
Paik, Julie M. [2 ,3 ]
机构：
[1] Lilly Deutschland GmbH, Global Med Affairs, Bad Homburg, Germany
[2] HMS, BWH, Boston, MA USA
[3] Div Pharmacoepidemiol, Boston, MA USA
[4] HMS, MGH, Boston, MA USA
[5] MGH Diabet Ctr, Boston, MA USA
[6] Boehringer Ingelheim Int GmbH, Corp Dept Global Epidemiol, Ingelheim, Germany
来源：
INNERE MEDIZIN | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P21-09
引用
收藏
页码：S149 / S149
页数：1
相关论文
共 50 条
  • [41] GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
    Giugliano, Dario
    Scappaticcio, Lorenzo
    Longo, Miriam
    Bellastella, Giuseppe
    Esposito, Katherine
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [42] Effectiveness and Tolerability Profile of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes
    Gorgojo-Martinez, Juan J.
    Feo-Ortega, Gara
    Serrano-Moreno, Clara
    Sanz-Velasco, Alberto
    DIABETES, 2016, 65 : A573 - A573
  • [43] GLP-1 Receptor Agonists Improve Cardiovascular Outcomes in Patients With Celiac Disease and Obesity
    Nieto, Luis
    Narvaez, Sharon
    Shepherd, Katherine
    Adeniran, Olanrewaju
    Vega, Kenneth
    Haggerty, Treah
    Davisson, Laura
    OBESITY, 2024, 32 : 87 - 88
  • [44] Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors Compared with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
    Edmonston, Daniel
    Mulder, Hillary
    Lydon, Elizabeth
    Chiswell, Karen
    Lampron, Zachary
    Shay, Christina M.
    Marsolo, Keith
    Bosworth, Hayden B.
    Pagidipati, Neha
    DIABETES, 2024, 73
  • [45] Indirect Treatment Comparison (ITC) of IGlarLixi vs. IDegLira in Adults Inadequately Controlled by GLP-1 Receptor Agonists (GLP-1RAs)
    Home, Philip
    Aroda, Vanita R.
    Fazeli, Mir Sohail
    Whittington, Craig
    Goswami, Hardik
    Shaunik, Alka
    Pourrahmat, Mir-Masoud
    Blonde, Lawrence
    Kalra, Sanjay
    DIABETES, 2020, 69
  • [46] Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease
    Tang, Mengyao
    Morieri, Mario Luca
    Kalim, Sahir
    Doria, Alessandro
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2025,
  • [47] Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists
    Prattichizzo, Francesco
    Candia, Paola de
    Ceriello, Antonio
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 120
  • [48] Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes
    Foer, Dinah
    Strasser, Zachary H.
    Cui, Jing
    Cahill, Katherine N.
    Boyce, Joshua A.
    Murphy, Shawn N.
    Karlson, Elizabeth W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 208 (10) : 1088 - 1100
  • [49] The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists
    van Baar, Michael J. B.
    van der Aart, Annemarie B.
    Hoogenberg, Klaas
    Joles, Jaap A.
    Heerspink, Hiddo J. L.
    van Raalte, Daniel H.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2019, 10
  • [50] Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta-analysis
    Kelly, Michael
    Lewis, Jelena
    Rao, Hindu
    Carter, Jessica
    Portillo, Ivan
    Beuttler, Richard
    PHARMACOTHERAPY, 2022, 42 (12): : 921 - 928
12345